ABCA1 p.Val93Cys
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 18359958
[PubMed]
Faulkner LE et al: "An analysis of the role of a retroendocytosis pathway in ABCA1-mediated cholesterol efflux from macrophages."
No.
Sentence
Comment
131
The V93C mutant was chosen for further studies because it exhibited the highest levels of expression in our recombinant system.
X
ABCA1 p.Val93Cys 18359958:131:4
status: NEW132 1324 Journal of Lipid Research Volume 49, 2008 atHealthScienceLibraryCB#7585,onSeptember24,2012www.jlr.orgDownloadedfrom 0.DC1.html Next, the ability to visualize fluorescent apoA-I (V93C) within RAW264.7 macrophages treated with cAMP to induce expression of ABCA1 was assessed.
X
ABCA1 p.Val93Cys 18359958:132:149
status: NEWX
ABCA1 p.Val93Cys 18359958:132:184
status: NEW133 Panels 1 and 2 of Fig. 2A show an optical slice taken through the center of the macrophage by confocal microscopy after incubation with fluorescent apoA-I (V93C) for 2 h.
X
ABCA1 p.Val93Cys 18359958:133:156
status: NEW143 To evaluate this possibility, the effect of cAMP treatment on the uptake of dextran polymers labeled with the identical Alexa Fluor 546 probe as that present on our apoA-I (V93C) was studied.
X
ABCA1 p.Val93Cys 18359958:143:173
status: NEW181 Colocalization of Alexa Fluor apoA-I (V93C) with LysoTracker Green in RAW cells.
X
ABCA1 p.Val93Cys 18359958:181:38
status: NEW190 Then, either 10 mg/ml Alexa Fluor-labeled apoA-I (V93C) 6 400 mg/ml unlabeled apoA-I competitor, or 18 mg/ml Alexa Fluor-labeled dextran beads were added 6 0.3 mM cAMP for 2 h.
X
ABCA1 p.Val93Cys 18359958:190:50
status: NEW224 Pulse-chase incubation of Alexa Fluor apoA-I (V93C) in RAW cells.
X
ABCA1 p.Val93Cys 18359958:224:46
status: NEW223 Pulse-chase incubation of Alexa Fluor apoA-I (V93C) in RAW cells.
X
ABCA1 p.Val93Cys 18359958:223:46
status: NEW
PMID: 15358601
[PubMed]
Le Goff W et al: "Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I."
No.
Sentence
Comment
50
ApoAI Uptake, Degradation, and Resecretion Assay Radiolabeling of 140 g of human ApoAI (specific activity 3620 cpm/ng) and assay of [125 I]apoAI uptake, degradation, and resecretion were performed as previously described.21 Uptake of Alexa568-labeled apoAI, processing, fixation, and DAPI counterstaining were as previously described,19 with the following modifications: an N-terminal His tagged ApoAI V93C substitution was created and purified by standard methods22 and labeled with Alexa 568 Maleimide (Molecular Probes).
X
ABCA1 p.Val93Cys 15358601:50:410
status: NEW44 ApoAI Uptake, Degradation, and Resecretion Assay Radiolabeling of 140 òe;g of human ApoAI (specific activity 3620 cpm/ng) and assay of [125 I]apoAI uptake, degradation, and resecretion were performed as previously described.21 Uptake of Alexa568-labeled apoAI, processing, fixation, and DAPI counterstaining were as previously described,19 with the following modifications: an N-terminal His tagged ApoAI V93C substitution was created and purified by standard methods22 and labeled with Alexa 568 Maleimide (Molecular Probes).
X
ABCA1 p.Val93Cys 15358601:44:409
status: NEW